126 related articles for article (PubMed ID: 15135735)
1. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges.
Harandi AM
J Clin Virol; 2004 Jul; 30(3):207-10. PubMed ID: 15135735
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
Tengvall S; Josefsson A; Holmgren J; Harandi AM
J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
[TBL] [Abstract][Full Text] [Related]
3. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.
Tengvall S; Harandi AM
J Reprod Immunol; 2008 Jun; 78(1):49-57. PubMed ID: 17945349
[TBL] [Abstract][Full Text] [Related]
4. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
5. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA
J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
[TBL] [Abstract][Full Text] [Related]
6. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
Gill N; Rosenthal KL; Ashkar AA
J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
[TBL] [Abstract][Full Text] [Related]
7. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.
Kwant A; Rosenthal KL
Vaccine; 2004 Aug; 22(23-24):3098-104. PubMed ID: 15297061
[TBL] [Abstract][Full Text] [Related]
8. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.
Ashkar AA; Yao XD; Gill N; Sajic D; Patrick AJ; Rosenthal KL
J Infect Dis; 2004 Nov; 190(10):1841-9. PubMed ID: 15499542
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
[TBL] [Abstract][Full Text] [Related]
11. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).
McCluskie MJ; Cartier JL; Patrick AJ; Sajic D; Weeratna RD; Rosenthal KL; Davis HL
Antiviral Res; 2006 Feb; 69(2):77-85. PubMed ID: 16377001
[TBL] [Abstract][Full Text] [Related]
12. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
Harandi AM; Holmgren J
Curr Opin Investig Drugs; 2004 Feb; 5(2):141-5. PubMed ID: 15043387
[TBL] [Abstract][Full Text] [Related]
13. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.
Ashkar AA; Bauer S; Mitchell WJ; Vieira J; Rosenthal KL
J Virol; 2003 Aug; 77(16):8948-56. PubMed ID: 12885911
[TBL] [Abstract][Full Text] [Related]
14. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.
Harandi AM; Eriksson K; Holmgren J
J Virol; 2003 Jan; 77(2):953-62. PubMed ID: 12502811
[TBL] [Abstract][Full Text] [Related]
15. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
16. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
[TBL] [Abstract][Full Text] [Related]
17. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.
Tengvall S; Lundqvist A; Eisenberg RJ; Cohen GH; Harandi AM
J Virol; 2006 Jun; 80(11):5283-91. PubMed ID: 16699008
[TBL] [Abstract][Full Text] [Related]
18. Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection.
Hendrickson BA; Guo J; Brown I; Dennis K; Marcellino D; Hetzel J; Herold BC
Virology; 2000 May; 271(1):155-62. PubMed ID: 10814580
[TBL] [Abstract][Full Text] [Related]
19. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
Lindqvist M; Persson J; Thörn K; Harandi AM
J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797
[TBL] [Abstract][Full Text] [Related]
20. Innate immunity to herpes simplex virus type 2.
Duerst RJ; Morrison LA
Viral Immunol; 2003; 16(4):475-90. PubMed ID: 14733735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
